title: Nanocell targeting using engineered bispecific antibodies.
abstract: There are many design formats for bispecific antibodies (BsAbs), and the best design choice is highly dependent on the final application. Our aim was to engineer BsAbs to target a novel nanocell (EnGeneIC Delivery Vehicle or EDV(TM)nanocell) to the epidermal growth factor receptor (EGFR). EDV(TM)nanocells are coated with lipopolysaccharide (LPS), and BsAb designs incorporated single chain Fv (scFv) fragments derived from an anti-LPS antibody (1H10) and an anti-EGFR antibody, ABX-EGF. We engineered various BsAb formats with monovalent or bivalent binding arms and linked scFv fragments via either glycine-serine (G4S) or Fc-linkers. Binding analyses utilizing ELISA, surface plasmon resonance, bio-layer interferometry, flow cytometry and fluorescence microscopy showed that binding to LPS and to either soluble recombinant EGFR or MDA-MB-468 cells expressing EGFR, was conserved for all construct designs. However, the Fc-linked BsAbs led to nanocell clumping upon binding to EDV(TM)nanocells. Clumping was eliminated when additional disulfide bonds were incorporated into the scFv components of the BsAbs, but this resulted in lower BsAb expression. The G4S-linked tandem scFv BsAb format was the optimal design with respect to EDV binding and expression yield. Doxorubicin-loaded EDV(TM)nanocells actively targeted with tandem scFv BsAb in vivo to MDA-MB-468-derived tumors in mouse xenograft models enhanced tumor regression by 40% compared to passively targeted EDV(TM)nanocells. BsAbs therefore provide a functional means to deliver EDV(TM)nanocells to target cells.
authors.affiliation: a Australian Institute for Bioengineering and Nanotechnology (AIBN) ; University of Queensland, St Lucia ; Queensland , Australia.
authors.forename: Karin
authors.initials: K
authors.lastname: Taylor
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Howard
authors.forename: Martina L
authors.initials: ML
authors.lastname: Jones
authors.forename: Ilya
authors.initials: I
authors.lastname: Sedliarou
authors.forename: Jennifer
authors.initials: J
authors.lastname: MacDiarmid
authors.forename: Himanshu
authors.initials: H
authors.lastname: Brahmbhatt
authors.forename: Trent P
authors.initials: TP
authors.lastname: Munro
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Mahler
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D000912:Antibodies, Neoplasm / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000276:immunology*; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D057127:Single-Chain Antibodies / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
chemical_list: D018033:Antibodies, Bispecific; D000912:Antibodies, Neoplasm; D011994:Recombinant Proteins; D057127:Single-Chain Antibodies; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: BsAb, bispecific antibody; EDVTM, EnGeneIC Delivery Vehicle; EGFR, epidermal growth factor receptor; IgG, immunoglobulin G; LPS, lipopolysaccharide; NP, nanoparticle; bispecific antibody; disulfide bridge; mAb, monoclonal antibody; mammalian expression; nanoparticle; scFv, single chain variable fragment; single chain Fv; surface plasmon resonance; tumor regression